Roles of Glucagon-like Peptide-1 in Skin Health and Disease
Updated
Abstract
GLP-1 receptor agonists (GLP-1RAs) may improve wound healing and reduce inflammation in skin conditions.
- GLP-1RAs have shown promising anti-inflammatory effects.
- Improvements were noted in conditions such as psoriasis and hidradenitis suppurativa.
- Common adverse reactions included injection site itching, redness, and rash.
- Current knowledge is primarily based on case reports and small-scale studies.
- The potential benefits of GLP-1RAs in dermatology may extend beyond blood glucose control.
Simplified
Funding
Competing interests
DISCLOSURES: Dr. Issa has served as a consultant and advisor for Eli Lilly and Company. Dr. Del Rosso has served as an investigator, consultant, advisor, and/or speaker for Galderma, Abbvie, Aclaris, Almirall, Amgen, Anaptys Bio, Arcutis, Athenex, Bausch, Biofrontera, Biopharmx, Biorasi, Blue Creek, Botanix, Brickell, Bristol Meyers Squibb, Cara Therapeutics, Cassiopea, Dermata, Dermavant, Encore, Epi Health, Evommune, Ferndale, Genentech, Incyte, JEM Health, Leo Pharma, La Roche Posay, Lilly, MC2, Novan, Pfizer, Ralexar, Regeneron, Sanofi-Genzyme, Sente, SolGel, Sonoma, Sun Pharma, Trevi, UCB, Verrica, and Vyne.
PubMed